To investigate the cellular response to AZD1775 and explore the contributions of KRAS genomic status to its effects, we used KRASMUT NSCLC cell lines with previously defined TP53 and STK11 status. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.